Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

UDIT NARAIN VERMA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1033178165
CMS profile
1104572
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$5,479.75

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,400.00 1
Travel and Lodging $816.39 2
Food and Beverage $263.36 5

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $5,479.75 8

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

UDIT NARAIN VERMA

NPI 1033178165 · CMS profile ID 1104572

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033178165?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
UDIT NARAIN VERMA, NPI 1033178165, CMS profile ID 1104572. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033178165?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). UDIT NARAIN VERMA, NPI 1033178165, CMS profile ID 1104572. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033178165?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
UDIT NARAIN VERMA, NPI 1033178165, CMS profile ID 1104572, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1033178165?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $5,479.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $4,400.0011/15/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651321161 CMS
E.R. Squibb & Sons, L.L.C. $30.0111/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651321179 CMS
E.R. Squibb & Sons, L.L.C. $50.0011/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651321181 CMS
E.R. Squibb & Sons, L.L.C. $83.3411/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651321183 CMS
E.R. Squibb & Sons, L.L.C. $60.0011/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651321185 CMS
E.R. Squibb & Sons, L.L.C. $40.0111/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651321187 CMS
E.R. Squibb & Sons, L.L.C. $230.6311/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651321175 CMS
E.R. Squibb & Sons, L.L.C. $585.7611/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651321177 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,479.75 8
PY2021 $366.18 2
PY2022 $116.79 2
PY2024 $2,020.00 2
PY2025 $19.68 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $91,962.90 72
PY2020 Principal investigator $39,950.14 23
PY2019 Principal investigator $52,486.64 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $921.00 09/01/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842910461
Principal investigator 1 EMD Serono, Inc. $921.00 09/01/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842910525
Principal investigator 1 EMD Serono, Inc. $875.00 08/17/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842909135
Principal investigator 1 EMD Serono, Inc. $162.00 08/17/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842909213
Principal investigator 1 EMD Serono, Inc. $921.00 08/02/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842910303
Principal investigator 1 EMD Serono, Inc. $921.00 08/02/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842910385
Principal investigator 1 EMD Serono, Inc. $4,940.00 07/02/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842913655
Principal investigator 1 EMD Serono, Inc. $921.00 07/01/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842910077
Principal investigator 1 EMD Serono, Inc. $92.10 07/01/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842910473
Principal investigator 1 EMD Serono, Inc. $921.00 07/01/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842910659
Principal investigator 1 EMD Serono, Inc. $921.00 04/21/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842929931
Principal investigator 1 EMD Serono, Inc. $921.00 04/21/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930165
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842927571
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842927599
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842927699
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842927741
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842927763
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842927875
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842927937
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842927961
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928003
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928065
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928081
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928123
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928141
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928169
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928175
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928237
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928315
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928343
Principal investigator 1 EMD Serono, Inc. $65.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928505
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928511
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928555
Principal investigator 1 EMD Serono, Inc. $11,728.80 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928609
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928639
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928669
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928685
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928701
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928775
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928803
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928835
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928873
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928923
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928927
Principal investigator 1 EMD Serono, Inc. $121.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842928999
Principal investigator 1 EMD Serono, Inc. $65.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842929617
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842931949
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842931979
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842932049
Principal investigator 1 EMD Serono, Inc. $1,056.00 04/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842932119
Principal investigator 1 EMD Serono, Inc. $6,500.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842929925
Principal investigator 1 EMD Serono, Inc. $3,250.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930031
Principal investigator 1 EMD Serono, Inc. $250.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930043
Principal investigator 1 EMD Serono, Inc. $350.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930159
Principal investigator 1 EMD Serono, Inc. $5,785.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842930335
Principal investigator 1 EMD Serono, Inc. $2,048.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930347
Principal investigator 1 EMD Serono, Inc. $1,950.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930365
Principal investigator 1 EMD Serono, Inc. $650.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930383
Principal investigator 1 EMD Serono, Inc. $2,500.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930389
Principal investigator 1 EMD Serono, Inc. $1,500.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930559
Principal investigator 1 EMD Serono, Inc. $2,500.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930699
Principal investigator 1 EMD Serono, Inc. $3,000.00 04/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842930841
Principal investigator 1 EMD Serono, Inc. $65.00 01/21/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842905331
Principal investigator 1 EMD Serono, Inc. $65.00 01/21/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842905347
Principal investigator 1 EMD Serono, Inc. $65.00 01/21/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842905527
Principal investigator 1 Novartis Pharmaceuticals Corporation $650.00 01/14/2021 Non-covered Recipient Entity
UNIVERSITY TEXAS SOUTHWESTERN MEDICAL CENTER
A RANDOMIZED DOUBLE BLIND MULTICENTER PHASE III STUDY OF EVEROLIMUS RAD001 PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN THE TREATMENT OF PATIENTS WITH ADVANCED NET OF GI OR LUNG ORIGIN No dispute reported 06/30/2026 800649177
Principal investigator 1 EMD Serono, Inc. $3,640.00 01/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842902285
Principal investigator 1 EMD Serono, Inc. $1,056.00 01/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842905131
Principal investigator 1 EMD Serono, Inc. $1,056.00 01/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842905445
Principal investigator 1 EMD Serono, Inc. $1,056.00 01/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842905611
Principal investigator 1 EMD Serono, Inc. $65.00 01/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842905640
Principal investigator 1 EMD Serono, Inc. $121.00 01/06/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic,adenocarcinoma of the stomach, or of the gastro-esophageal junction No dispute reported 06/30/2026 842905805